Strategic Partnerships MEDIPOST is actively expanding through collaborations and licensing, including a non-exclusive MOU with Charles River Laboratories to advance GMP testing solutions and the exclusive license in Japan with Teikoku Seiyaku. Target opportunities include co-development, CDMO services, and regional commercialization partnerships to accelerate CARTISTEM adoption.

Global Manufacturing OmniaBio, a joint venture CDMO built with CCRM, positions MEDIPOST to offer contract development and manufacturing for cell and gene therapies. Sales prospects include CDMO partnerships for CARTISTEM manufacturing scale-up, process optimization, and potential white-labeling or co-branded manufacturing agreements.

Late-Stage US Opportunity With CARTISTEM entering late-stage development for knee osteoarthritis in the United States, there is a strong sales case for trials support, regulatory consulting, and payer strategy services, as well as potential US commercialization partnerships and manufacturing readiness services.

Financing Momentum Recent $140M funding signals investor confidence and capacity for continued clinical and commercial expansion. Leverage this momentum to pursue strategic investments, joint ventures, and co-funding opportunities for cartilage repair therapies and related inflammation-driven indications.

Geographic Expansion Exclusive Japan commercialization rights for CARTISTEM and ongoing international partnerships suggest opportunities to broaden market access, distribution agreements, and regional regulatory support services, particularly in Asia-Pacific and North America through CDMO and licensing deals.